<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602715</url>
  </required_header>
  <id_info>
    <org_study_id>MET-2 301-2</org_study_id>
    <nct_id>NCT04602715</nct_id>
  </id_info>
  <brief_title>The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression</brief_title>
  <official_title>The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuBiyota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NuBiyota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To measure the effects of Microbial Ecosystem Therapeutics (MET)-2 on symptoms of depression&#xD;
      and anxiety using pre- and post-treatment scores for overall depression and anxiety&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An eight week, randomized, placebo controlled trial to assess subjective changes in mood and&#xD;
      anxiety symptoms from baseline to after MET-2 treatment in participants with depression,&#xD;
      using MADRS, Hamilton Anxiety Rating Scale (HAM-A), and other mood/anxiety scales and to&#xD;
      demonstrate a significantly higher proportion of responders in patient who were randomized to&#xD;
      receive the active study drug compared to patients who were randomized to receive placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two arm, randomized, placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Hospital pharmacies will be provided with the randomization code and will dispense the appropriate medication to subjects. A fire-wall exists between the pharmacies and the investigational staff.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Major Depression Symptoms</measure>
    <time_frame>Baseline vs. Week 6</time_frame>
    <description>To assess subjective changes in mood from baseline to after MET-2 treatment using the Montgomery-Asberg Depression Rating Scale (10 domains given a rating from 0 to 6)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Anxiety Symptoms</measure>
    <time_frame>Baseline vs. Week 6</time_frame>
    <description>To assess subjective changes in anxiety symptoms from baseline to after MET-2 treatment using the Hamilton Anxiety Rating Scale (14 domains given a rating on a 5 point scale)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>MET-2 20 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose of MET-2 is administered for the first two days, followed by a regular, daily dose for the duration of the study (6 weeks total).The loading dose will consist of 5 g of MET-2 in the form of ten capsules orally on day one and on day two. The regular daily dose will consist of 1.5 g MET-2 in the form of three MET-2 capsules taken once daily, excluding days where they take the booster (same as loading dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Loading dose of placebo is administered for the first two days, followed by a regular, daily dose of placebo for the duration of the study (6 weeks total).The loading dose will consist of ten capsules of placebo (which match the MET-2 capsules in appearance and weight) taken orally on day one and on day two. The regular daily dose will consist of three placebo capsules taken once daily, excluding days where they take the booster (same as loading dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MET-2</intervention_name>
    <description>Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.</description>
    <arm_group_label>MET-2 20 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide informed consent.&#xD;
&#xD;
          2. Not pregnant&#xD;
&#xD;
          3. Willing to participate in follow up as part of the study&#xD;
&#xD;
          4. Diagnosis of Major Depressive Disorder (MDD) by the Mini-International&#xD;
             Neuropsychiatric Interview (MINI)&#xD;
&#xD;
          5. Current depressive episode with a Montgomery-Asberg Depression Rating Scale (MADRS)&#xD;
             score of â‰¥15.&#xD;
&#xD;
          6. Able to understand and comply with the requirements of the study&#xD;
&#xD;
          7. Able to provide stool, urine, and blood samples.&#xD;
&#xD;
          8. Those who do not choose to use antidepressants for moderate-severe depression.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of chronic diarrhea&#xD;
&#xD;
          2. Need for regular use of agents that affect gastro-intestinal (GI) motility (narcotics&#xD;
             such as codeine or morphine, agents such as loperamide or metoclopramide)&#xD;
&#xD;
          3. Colostomy&#xD;
&#xD;
          4. Elective surgery that will require preoperative antibiotics planned within 6 months of&#xD;
             enrolment&#xD;
&#xD;
          5. History of bariatric surgery.&#xD;
&#xD;
          6. Pregnant, breastfeeding, or planning to get pregnant in the next 6 months&#xD;
&#xD;
          7. Any condition for which, in the opinion of the investigator, the participant should be&#xD;
             excluded from the study.&#xD;
&#xD;
          8. Current use of any antidepressant/antianxiety drug (eligible to participate after a&#xD;
             4-week washout period)&#xD;
&#xD;
          9. More than three depressive episodes throughout lifetime&#xD;
&#xD;
         10. Having failed an anti-depressant treatment during current depressive episode&#xD;
&#xD;
         11. Use of any antibiotic drug in the past 4 weeks (may be eligible to participate after a&#xD;
             1-month washout period)&#xD;
&#xD;
         12. History of alcohol or substance dependence in the past 6 months&#xD;
&#xD;
         13. Daily use of probiotic product in the past 2 weeks (may be eligible to participate&#xD;
             after a 2-week washout period)&#xD;
&#xD;
         14. Use of any type of laxative in the last 2 weeks.&#xD;
&#xD;
         15. Consumption of products fortified in probiotics (may be eligible to participate after&#xD;
             a 2-week washout period)&#xD;
&#xD;
         16. High suicidal risk, as measured by MADRS item 10 score more than 3&#xD;
&#xD;
         17. Current psychotic symptoms&#xD;
&#xD;
         18. Bipolar Depression&#xD;
&#xD;
         19. History of epilepsy or uncontrolled seizures&#xD;
&#xD;
         20. Immunodeficiency (immuno-compromised and immuno-suppressed participants; e.g. acquired&#xD;
             immune deficiency syndrome [AIDS], lymphoma, participants undergoing long-term&#xD;
             corticosteroid treatment, chemotherapy and allograft participants)&#xD;
&#xD;
         21. Unstable medical conditions or serious diseases/conditions (e.g. cancer,&#xD;
             cardiovascular, renal, lung, diabetes, psychiatric illness, bleeding disorders, etc.)&#xD;
&#xD;
         22. The use of natural health products (NHP); e.g. St. John's Wort, passion flower, etc.)&#xD;
             that affect depression&#xD;
&#xD;
         23. History of Electroconvulsive therapy (ECT)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roumen Milev, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queens University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arthi C Meyyappan, MSc</last_name>
    <phone>647.226.2803</phone>
    <email>meyyappa@providencecare.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roumen Milev, MD/PhD</last_name>
    <phone>613.544.4900</phone>
    <phone_ext>73002</phone_ext>
    <email>milevr@providencecare.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Providence Care Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassandra Sgarbossa, BSc</last_name>
      <phone>(519) 404-4326</phone>
      <email>c.sgarbossa@queensu.ca</email>
    </contact>
    <contact_backup>
      <last_name>Roumen Milev, MD, PhD</last_name>
      <phone>(613) 544-4900</phone>
      <phone_ext>73002</phone_ext>
      <email>milevr@providencecare.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CAMH</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilona Gorbovskaya, MSc</last_name>
      <phone>416 535-8501</phone>
      <phone_ext>30231</phone_ext>
      <email>ilona.gorbovskaya@camh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Mueller, MD/PhD</last_name>
      <phone>416 535-8501</phone>
      <phone_ext>30851</phone_ext>
      <email>daniel.mueller@camh.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>May 9, 2021</last_update_submitted>
  <last_update_submitted_qc>May 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

